Evidence Grade A — Regulatory approved. 270 published studies. 8 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Nafarelin (sold as Synarel) is a hormone-suppressing medication delivered as a nasal spray — making it the only treatment in its class that avoids injections or implants entirely. It is used for endometriosis and central precocious puberty (early puberty in children), requiring two sprays per day. For people who strongly prefer to avoid needles, it offers a meaningful alternative.
Nafarelin is also known by these brand and alternate names:
270 published studies: 223 human, 28 animal, 32 in-vitro, 29 reviews
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children.
Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
Nafarelin works through the same GnRH agonist mechanism as injectable treatments like leuprolide — continuous exposure shuts down the body's sex hormone production after an initial brief surge. The key difference is its route of delivery: nafarelin is absorbed through the nasal lining, reaching the bloodstream without any needles. While only about 2–3% of the dose is absorbed this way, this is enough to produce full therapeutic hormone suppression.
Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, the twice-daily nasal spray schedule creates compliance challenges — missed doses and nasal congestion can both reduce effectiveness. This is a significant practical limitation compared to depot injections that work for one to six months from a single administration. Nafarelin has been largely overtaken by longer-acting injectable formulations (leuprolide, triptorelin) and the histrelin implant, which provide more reliable hormone suppression without depending on daily patient compliance. It remains available as a needle-free option for patients who cannot tolerate injections, but is no longer commonly prescribed.
PeptideTrace tracks 8 registered clinical trials for Nafarelin sourced from ClinicalTrials.gov.
Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone
Injection Free IVF
GnRH Agonist for Luteal Phase Support.
Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders
Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 3
FDA SUPPL 4
FDA SUPPL 5
FDA SUPPL 6
FDA SUPPL 10
FDA SUPPL 11
FDA SUPPL 12
Health Canada Market Authorisation
FDA SUPPL 13
FDA SUPPL 15
FDA SUPPL 17
FDA SUPPL 20
FDA SUPPL 19
FDA SUPPL 18
FDA SUPPL 21
FDA SUPPL 22
FDA SUPPL 26
FDA SUPPL 27
FDA SUPPL 30
FDA SUPPL 31
FDA SUPPL 32
FDA SUPPL 35
FDA SUPPL 33
FDA SUPPL 38
FDA SUPPL 39
FDA SUPPL 40
Nafarelin is a synthetic decapeptide (10 amino acids) GnRH agonist with a D-2-naphthylalanine substitution at position 6 (D-2Nal6), increasing potency approximately 200-fold relative to native GnRH. It is the only GnRH agonist administered via intranasal spray.
Nafarelin shares the standard GnRH agonist mechanism of continuous receptor stimulation → flare → downregulation → HPG axis suppression. Nasal mucosal absorption provides systemic bioavailability of approximately 2–3%, which is sufficient for therapeutic effect at the administered doses. Peak serum levels are reached within 10–45 minutes.
Nafarelin is marketed as Synarel (approved February 13, 1990). Indications include endometriosis (400 mcg/day, one spray each nostril BID, for 6 months) and central precocious puberty (1,600 mcg/day, two sprays each nostril BID/TID). It is the only intranasal GnRH agonist available in the US.
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019. The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Kisspeptin-54 has no marketing authorisation. Phase II trials conducted primarily at Imperial College London have investigated its use as an IVF oocyte maturation trigger. One trial (60 patients) reported 95% oocyte maturation with zero cases of ovarian hyperstimulation syndrome. Kisspeptin-54 has a more advanced clinical evidence base than kisspeptin-10, with multiple Phase II studies in reproductive medicine. Its potential advantage over conventional IVF triggers relates to a lower risk of the serious complication of ovarian hyperstimulation. Clinical development is ongoing in academic settings. No Phase III trials have been completed.
Goserelin is marketed as Zoladex by AstraZeneca, available as 3.6 mg monthly and 10.8 mg three-monthly subcutaneous implants. First approved in 1989, it is used in advanced prostate cancer, premenopausal breast cancer, endometriosis, and for thinning the uterine lining before surgical procedures. Goserelin achieves castrate-level testosterone suppression (below 50 ng/dL) within two to four weeks. Its unique implant delivery system means there is no liquid injection, reconstitution, or refrigeration required — a practical advantage in some clinical settings. Like all GnRH agonists, it causes an initial hormone flare before suppression takes effect. Goserelin holds an important niche in breast cancer treatment, where it is used to suppress ovarian function in premenopausal women with hormone-receptor-positive disease, often in combination with aromatase inhibitors.
Evidence Reviews
Regulatory Status
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
